We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Daiichi Sankyo Company Ltd (PK) | USOTC:DSNKY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.80 | -2.36% | 33.10 | 32.70 | 33.45 | 34.075 | 32.89 | 34.075 | 39,182 | 21:05:59 |
From Sep 2022 to Sep 2024
By Anthony O. Goriainoff
AstraZeneca and Daiichi Sankyo said that datopotamab deruxtecan, a cancer drug, combined with the Imfinzi cancer treatment--with or without chemotherapy--showed disease control rates of 92% and 93% respectively in patients with previously untreated advanced or metastatic non-small cell lung cancer.
The Anglo-Swedish pharma giant said Monday that the results reinforced its confidence in this being a potential treatment option for patients with this type of lung cancer.
"Three ongoing pivotal trials are evaluating datopotamab deruxtecan and immune checkpoint inhibitor combinations in first-line advanced non-small cell lung cancer," AstraZeneca said.
Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
September 11, 2023 02:40 ET (06:40 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Daiichi Sankyo (PK) Chart |
1 Month Daiichi Sankyo (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
